Efficacy and Safety of Nadifloxacin for Bacterial Skin Infections: Results from Clinical and Post-Marketing Studies

Dermatology and Therapy

Volumn 4, Issue 2, 2014, Pages 233-248

  Narayanan, Varsha ^a   Motlekar, Salman ^a   Kadhe, Ganesh ^a   Bhagat, Seema ^a  

^a Wockhardt Ltd   (India)

Author keywords

Bacterial skin infections; Dermatology; Fluoroquinolone; Nadifloxacin; SSTIs; Topical antibiotic

Indexed keywords

FRAMYCETIN; FUSIDIC ACID; NADIFLOXACIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL SKIN DISEASE; BURNING SENSATION; CHILD; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; EVENING DOSAGE; FEMALE; FOLLICULITIS; FURUNCULOSIS; HUMAN; IMPETIGO; INDIAN; INFANT; INFECTED ATOPIC DERMATITIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); OINTMENT; PAIN; POSTMARKETING SURVEILLANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SECONDARY INFECTION; SKIN PRURITUS; SKIN SWELLING; SYMPTOMATOLOGY; TREATMENT OUTCOME; WOUND FLUID; WOUND INFECTION;

EID: 84915822417     PISSN: 21938210     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-014-0062-1     Document Type: Article

References (38)

1. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol. 2008;19(2):173–84.
2. Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group. Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern. Indian J Med Res. 2013;137(2):363–9.
3. Hetem DJ, Bonten MJ. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect. 2013;85(4):249–56.
4. Gisby J, Bryant J. Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother. 2000;44(2):255–60.
5. Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents. 1999;12(Suppl 2):S59–66.
6. Takei M, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001;45(12):3544–7.
7. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol. 2006;16(1):48–55.
8. de Souza NJ, et al. A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. J Med Chem. 2005;48(16):5232–42.
9. Patel MV, et al. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother. 2004;48(12):4754–61.
10. Nenoff P, Haustein UF, Hittel N. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections. Chemotherapy. 2004;50(4):196–201.
11. Jacobs MR, Appelbaum PC. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother. 2006;7(14):1957–66.
12. Jacobs MR, et al. In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob Agents Chemother. 2004;48(9):3338–42.
13. Alba V, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. Int J Antimicrob Agents. 2009;33(3):272–5.
14. Choudhury S, et al. Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: a randomized controlled trial. Indian J Pharmacol. 2011;43(6):628–31.
15. Schöfer H, Göllner A, Kusche W, Schwantes U. Effectiveness and tolerance of topical nadifloxacin in the therapy of acne vulgaris (grade I–II): results of a non-interventional trial in 555 patients. J Appl Res. 2009;9:44–51.
16. Kobayashi M, et al. Efficacy of combined topical treatment of acne vulgaris with adapalene and nadifloxacin: a randomized study. J Dermatol. 2011;38(12):1163–6.
17. Haustein UF, Nenoff P, Hittel N. Topical quinolone nadifloxacin (OPC-7251) in bacterial skin disease: clinical evaluation in a multicenter open trial and in vitro anti microbiological susceptibility testing. J Dermatol Treat. 1997;8:87–92.
18. Jones RN. Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians? Diagn Microbiol Infect Dis. 1992;15(2):177–9.
19. Luke RG, Watson WC. Antibiotics in dermatology. Br Med J. 1963;2(5363):981–2.
20. Blondeau JM. The role of fluoroquinolones in skin and skin structure infections. Am J Clin Dermatol. 2002;3(1):37–46.
21. Koga H, et al. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J Med Chem. 1980;23(12):1358–63.
22. Chu DT, Fernandes PB. Structure–activity relationships of the fluoroquinolones. Antimicrob Agents Chemother. 1989;33(2):131–5.
23. Gollnick HPM, Vogt K, Hermann J, et al. Topical quinolone OPC-7251: a clinical and microbiological study in acne. Eur J Dermatol. 1994;4:210–15.
24. Kurokawa I, et al. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol. 1991;25(4):674–81.
25. Kimata H. Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children. Eur J Pediatr. 1999;158(11):949.
26. Vogt K, et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. Eur J Clin Microbiol Infect Dis. 1992;11(10):943–5.
27. Deng X, et al. Expression of multidrug resistance efflux pump gene norA is iron responsive in Staphylococcus aureus. J Bacteriol. 2012;194(7):1753–62.
28. Morrow BJ, et al. Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011;55(12):5512–21.
29. Guilhelmelli F, et al. Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol. 2013;4:353.
30. Oizumi N, et al. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J Infect Chemother. 2001;7(3):191–4.
31. Madhusudhan KT, et al. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test. Chemotherapy. 2003;49(4):184–8.
32. Raviglione MC, et al. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990;34(11):2050–4.
33. Chang SC, et al. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains. Diagn Microbiol Infect Dis. 2000;36(2):131–6.
34. Rist T, et al. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol. 2002;27(1):14–20.
35. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193–209.
36. Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr Med Res Opin. 2007;23(6):1403–13.
37. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33(5):353–69.
38. Jung JY, et al. Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol. 2011;50(3):350–7.